BIG
IMVT icon

Brooklyn Investment Group’s Immunovant IMVT Stock Holding History

Brooklyn Investment Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,720
Closed -$108K – 1636
2025
Q2 		$108K Buy
+6,720
New +$102K 0.01% 901

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Brooklyn Investment Group's IMVT Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Immunovant (IMVT) in Q3 2025, closing a stake of 6,720 shares — an estimated $108K sold.

Brooklyn Investment Group first reported a position in IMVT in Q2 2025 and held it in 1 quarter. The position peaked at $108K in Q2 2025. 186 funds tracked by Wall St. Rank hold IMVT as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Immunovant position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 6,720 Immunovant shares in Q3 2025, an estimated $108K.
  • Brooklyn Investment Group first reported a position in Immunovant in Q2 2025 and held it in 1 quarter.
  • Brooklyn Investment Group's Immunovant position peaked at $108K in Q2 2025.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.